TriangleNCT03000179 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Every 3 months after completing treatment up to 5 years
What was measured
On study date until death from any cause
Analysis population: all participants
Groups in this outcome
Avelumab Monotherapy
Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks. Avelumab: Avelumab through a vein once every 2 weeks
| Group | Source count |
|---|---|
| Avelumab Monotherapy | 8 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Avelumab Monotherapy | 6.4 | Not reported | 3.8 | NA | Insufficient number of patients with the death event |
Complete source fields
- classes
- categories
- measurements
- comment
- Insufficient number of patients with the death event
- group Id
- OG000
- lower Limit
- 3.8
- upper Limit
- NA
- value
- 6.4
- denoms
- counts
- group Id
- OG000
- value
- 8
- units
- Participants
- description
- On study date until death from any cause
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks. Avelumab: Avelumab through a vein once every 2 weeks
- id
- OG000
- title
- Avelumab Monotherapy
- param Type
- MEDIAN
- population Description
- all participants
- reporting Status
- POSTED
- time Frame
- Every 3 months after completing treatment up to 5 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice